Held in Chicago, ACC 2025 is the premier event for exploring breakthroughs in cardiovascular research. Attendees will benefit from high-impact sessions, hands-on workshops, and networking opportunities. Our team will share key insights and discuss initiatives aimed at addressing challenges in heart health. Whether you’re looking to expand your research capabilities or collaborate on innovative treatments, we’re eager to connect with you.
Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1
March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
